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Background: Selective and potent positive allosteric modulators (PAMs) of the M1 mAChR have been recently described.
Results: Use of structural analogues and mutagenic mapping identified the mechanistic basis for increased PAM activity.
Conclusion: Combined analytical, structure-function, and modeling approaches uncover allosteric mechanisms at the M1
mAChR.
Significance: New chemical space can be explored in the development of tailored M1 mAChR PAMs.
Benzylquinolone carboxylic acid (BQCA) is the first highly
selective positive allostericmodulator (PAM) for theM1musca-
rinic acetylcholine receptor (mAChR), but it possesses lowaffin-
ity for the allosteric site on the receptor. More recent drug
discovery efforts identified 3-((1S,2S)-2-hydroxycyclohexyl)-6-
((6-(1-methyl-1H-pyrazol-4-yl)pyridin-3-yl)methyl)benzo[h]-
quinazolin-4(3H)-one (referred to herein as benzoquinazolin-
one 12) as a more potent M1 mAChR PAM with a structural
ancestry originating fromBQCA and related compounds. In the
current study, we optimized the synthesis of and fully character-
ized the pharmacology of benzoquinazolinone 12, finding that
its improved potency derived from a 50-fold increase in allo-
steric site affinity as compared with BQCA, while retaining a
similar level of positive cooperativity with acetylcholine. We
then utilized site-directedmutagenesis andmolecularmodeling
to validate the allosteric binding pocket we previously described
for BQCA as a shared site for benzoquinazolinone 12 and pro-
vide a molecular basis for its improved activity at the M1
mAChR. This includes a key role for hydrophobic and polar
interactions with residues Tyr-179, in the second extracellular
loop (ECL2) andTrp-4007.35 in transmembrane domain (TM) 7.
Collectively, this study highlights how the properties of affinity
and cooperativity can be differentially modified on a common
structural scaffold and identifies molecular features that can be
exploited to tailor the development of M1 mAChR-targeting
PAMs.
Gprotein-coupled receptors (GPCRs)7 are the largest class of
cell surface receptors and mediate major physiological pro-
cesses. With over 800 GPCRs encoded by the human genome,
they are the target of more than 30% of currently marketed
drugs (1). The M1 mAChR is one of five muscarinic receptor
subtypes that belong to the family A GPCRs (2). Numerous
drug discovery efforts have focused on developing selective
ligands for this receptor subtype as potential therapies for neu-
rocognitive disorders, such as Alzheimer’s disease and schizo-
phrenia (3, 4). Efforts aimed at targeting the highly conserved
orthosteric (ACh) binding site have largely failed because of a
lack of ligand subtype selectivity, whereas those targeting topo-
graphically distinct allosteric sites have provenmore fruitful (5,
6). However, allosteric ligands can display complex behaviors,
modulating orthosteric ligand affinity or efficacy and/or dis-
playing direct agonism in their own right. A surge in family A
GPCR crystal structures has provided considerable insights
into the location of orthosteric binding pockets and the molec-
ular mechanisms underlying ligand binding and receptor acti-
vation (7, 8). Of particular interest, the recent solution of a
crystal structure of theM2mAChR co-bound with an allosteric
modulator and an orthosteric agonist has given the first snap-
shot of a mechanism by which a modulator can act to enhance
orthosteric agonist affinity (9). However, such information is
currently lacking for other GPCRs, and both the structural and
dynamic bases of how allosteric modulation is transmitted
between spatially distinct binding sites remain largely unex-
plored. Thus, a combination of structure-activity and struc-
ture-function studies of GPCR allostery remains a vital
approach to addressing some of these challenges, provided that
this approach is enriched by analyticalmethods that can dissect
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structural effects on ligand binding from transmission of coop-
erativity and receptor activation.
In a recent study, we combined site-directed mutagenesis,
analytical modeling, and molecular dynamics to delineate
regions of theM1mAChR governing actions of the prototypical
positive allosteric modulator, BQCA (10). This compound has
emerged as a useful tool because it displays absolute subtype
selectivity for the M1 mAChR, has a very high positive cooper-
ativitywithACh, displays amechanismof action that appears in
strict accordance with a simple two-state model of receptor
activity (11), and has shown in vivo efficacy (6, 12). We identi-
fied several residues that contribute to the BQCA binding
pocket as well as to the transmission of cooperativity with the
orthosteric agonist, carbachol. Such residues were located in
the ECL2 and at the top of TM2 and TM7. The BQCA binding
pocket was proposed to partially overlap with the previously
described “common” allosteric site in the extracellular vestibule
of mAChRs (9, 13–16), suggesting that its high subtype selec-
tivity derives from either additional contacts outside this region
or through a subtype-specific cooperativity mechanism (17).
Unfortunately, both the therapeutic utility of BQCA and
potential for deeper mechanistic insights into M1 mAChR
allostery afforded by this molecule remain limited, because
BQCA has a very low affinity for theM1mAChR in the absence
of co-bound agonist (11) and poor aqueous solubility. This has
mechanistic implications in that it limits the ability to utilize
loss of functionmutagenesis approaches to distinguish key res-
idues that governmodulator affinity (thus directly contributing
to the allosteric binding site) versus residues that contribute to
the transmission of the allosteric effect (thus indirectly contrib-
uting to the observed potency and selectivity). Such insights
would be greatly facilitated by the availability of higher affinity
allosteric probes. Encouragingly, recent drug discovery efforts
resulted in the disclosure of putative allosteric M1 mAChR
ligands with higher functional potency than BQCA, although
the mechanism of action remains to be definitively established
for a number of these compounds (18–23). One such com-
pound, 3-((1S,2S)-2-hydroxycyclohexyl)-6-((6-(1-methyl-1H-
pyrazol-4-yl)pyridin-3-yl)methyl)benzo[h]quinazolin-4(3H)-
one, referred to herein as benzoquinazolinone 12 (see Fig. 1), is
of particular interest, because it is structurally derived from
BQCA but has been reported to have substantially higher func-
tional potency, on the basis of preliminary characterization (24,
25). However, its ultimate mechanism of action and the struc-
tural basis for its higher potency remain undetermined.
In the current study, we developed an optimized synthesis of
benzoquinazolinone 12, report the first comprehensive phar-
macological characterization of its allosteric properties, anduse
site-directed mutagenesis of specific M1 mAChR amino acid
residues to determine ligand-receptor interactions that govern
the actions of this compound at theM1mAChR and explain its
improved allosteric properties in comparison to BQCA. We
also contextualize our experimental findings using molecular
modeling and find that many of the key residues that form the
allosteric binding pocket at the M1 mAChR are structurally
conserved in other mAChR subtypes (9, 13–15) and even other
GPCRs (26, 27). Collectively, our results highlight how allo-
steric selectivity can be attained not only via selective affinity
for a defined binding pocket but also by differential cooperativ-
ity between subtypes and can provide the basis for the design of
novel M1 mAChR-selective allosteric ligands.
EXPERIMENTAL PROCEDURES
Materials—CHO FlpIn cells and DMEM were purchased
from Invitrogen. FBS was purchased from ThermoTrace (Mel-
bourne, Australia). Hygromycin-B was purchased from Roche.
[3H]N-methylscopolamine ([3H]NMS); specific activity, 84.1
Ci/mmol) and MicroScint scintillation liquid were purchased
from PerkinElmer Life Sciences. IP-One assay kit and reagents
were purchased fromCisbio (Codolet, France). All other chem-
icals were purchased from Sigma-Aldrich. BQCA and benzo-
quinazolinone 12 were synthesized in house as described in the
supplemental materials.
Cell Culture and Receptor Mutagenesis—Mutations of the
c-myc-hM1 mAChR sequence were generated using the
QuikChange site-directed mutagenesis kit (Agilent Technolo-
gies, La Jolla, CA) following themanufacturer’s instructions. All
mutations were confirmed by DNA sequencing (Australian
Genome Research Facility, Melbourne, Australia). Mutant
c-myc-hM1 mAChR DNA constructs were transfected into
FlpIn CHO cells (Invitrogen) and selected using 0.2 mg/ml
hygromycin for stable expression.
Whole Cell Radioligand Binding Assays—Saturation binding
assays were performed using cells plated at 104 cells per well in
96-well Isoplates (PerkinElmer Life Sciences). The following
day, the cells were incubated with the orthosteric antagonist
[3H]NMS in a final volume of 100 l of HEPES buffer (10 mM
HEPES, 145 mM NaCl, 1 mM MgSO47H2O, 10 mM glucose, 5
mMKCl, 2 mMCaCl2, 1.5 mMNaHCO3, pH 7.4) for 2 h at room
temperature. For competition binding assays, cells were plated
at 2.5 104 cells/well. The following day, cells were incubated
in a final volume of 100 l of HEPES buffer containing increas-
ing concentrations of the competing cold ligand ACh (in the
absence or presence of increasing concentrations of the allo-
steric modulator) in a humidified incubator for 1.5 h at 37 °C in
the presence of 0.3 nM [3H]NMS. Nonspecific binding was
defined in the presence of 100Matropine. For all experiments,
termination of the assay was performed by rapid removal of
radioligand followed by two 100-l washes with ice-cold 0.9%
NaCl buffer. Radioactivitywas determined by addition of 100l
ofMicroscint scintillation liquid (PerkinElmer Life Sciences) to
each well and counting in a MicroBeta plate reader (Perkin-
Elmer Life Sciences).
IP-One Accumulation Assays—The IP-One assay kit (Cisbio,
France) was used for the direct quantitative measurement of
myo-inositol 1 phosphate (IP1) in FlpIn CHO cells stably
expressing either WT or mutant hM1 mAChRs. Cells were
seeded into 384-well Proxy plates (PerkinElmer Life Sciences)
at 7,500 cells/well. The following day cells were stimulated with
ACh in IP1 stimulation buffer (10 mM HEPES, 1 mM CaCl2, 0.5
mM MgCl2, 4.2 mM KCl, 146 mM NaCl, 5.5 mM glucose, 50 mM
LiCl, pH 7.4) in the absence or presence of increasing concen-
trations of the allosteric modulator and incubated for 1 h at
37 °C, 5% CO2. Cells were lysed by the addition of homogenous
time resolved FRET reagents, the cryptate-labeled anti-IP1
antibody, and the d2-labeled IP1 analogue, followed by incuba-
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tion for 1h at roomtemperature.The emission signalsweremeas-
ured at 590 and 665 nm after excitation at 340 nm using the Envi-
sion multilabel plate reader (PerkinElmer Life Sciences), and the
signalwasexpressedas thehomogenous timeresolvedFRETratio:
F ((fluorescence665 nm/fluorescence590 nm) 104). Experiments
usingWTM1mAChRCHOFlpIncellswereperformed inparallel
each day.
ComputationalMethods for theModel of the Ligand-Receptor
Complex—Our previously described hM1 mAChR model was
used for the structural study (10). Docking of the ligands was
performed using MOE (Molecular Operating Environment
Chemical Computing Group). ACh was docked manually into
the receptormodelwith the quaternized nitrogen of the choline
head group interacting with Asp3.32 and the ester group situ-
ated toward TMIII–TMVI, resembling the position of the
ligands described in the mAChR crystal structures (Protein
Data Bank codes 3UON (28) and 4DAJ (29)). Benzoquinazoli-
none 12 was docked into the hM1 mAChR allosteric binding
site described for BQCA. The complex was subjected to an
energy minimization using MMFF94X force field and was fur-
ther refined by means of MD simulations (performed with
NAMD2.9 (30) package) using a previously described protocol
(31).
Data Analysis—All data were analyzed using Prism 6.01
(GraphPad Software, SanDiego, CA). Inhibition binding curves
between [3H]NMS and unlabeled ligands were fitted to a one-
site binding model (32). Binding interaction studies with allo-
steric ligands were fitted to the following allosteric ternary
complex model (33),
Y 
BmaxA
A  KAKBB KB1 IKI  BKB  IBKIKB 
(Eq. 1)
where Y is the percentage (vehicle control) binding, Bmax is the
total number of receptors; [A], [B], and [I] are the concentra-
tions of radioligand, allosteric modulator, and the orthosteric
ligand, respectively; and KA, KB, and KI are the equilibrium dis-
sociation constants of the radioligand, allosteric modulator,
and orthosteric ligand, respectively.  and  are the binding
cooperativities between the allosteric modulator and radioli-
gand and the allosteric ligand and orthosteric ligand, respec-
tively. Values of  (or ) that are1 denote positive coopera-
tivity, values of1 (but0) denote negative cooperativity, and
a value of 1 denotes neutral cooperativity.
Concentration-response curves for the interaction between
the allosteric ligand and the orthosteric ligand in the IP-One
accumulation assays were globally fitted to the following oper-
ational model of allosterism and agonism (34),
E 
Em	AA	KB B
 BBKA

n
	AKB KAKB BKA AB

n
 	AA	KB B
 BBKA

n
(Eq. 2)
where Em is the maximum possible cellular response; [A] and
[B] are the concentrations of orthosteric and allosteric ligands,
respectively; KA and KB are the equilibrium dissociation con-
stant of the orthosteric and allosteric ligands, respectively; A
and B are operational measures of orthosteric and allosteric
ligand efficacy, respectively,  is the binding cooperativity
parameter between the orthosteric and allosteric ligand, and 
denotes the magnitude of the allosteric effect of the modulator
on the efficacy of the orthosteric agonist. Inmany instances, the
individualmodel parameters of Equation 2 could not be directly
estimated via the nonlinear regression algorithm by analysis of
the functional data alone, because of parameter redundancy. To
facilitate model convergence, therefore, we fixed the equilib-
rium dissociation constant of each ligand to that determined
from the whole cell binding assays. This practice assumes that
the affinity determined in the whole cell binding assays is not
significantly different from the “functional” affinity operative at
the level of the signaling assay, whichmaynot always be the case
(35) and thus may lead to a systematic error in the estimate of
the operational efficacy parameter, . However, because only a
single pathway (IP1) is being considered, the relativedifferences
between  values remain valid for statistical comparison
purposes.
All affinity, potency, and cooperativity values were estimated
as logarithms (36), and statistical comparisons between values
were by one-way analysis of variance using aDunnett’smultiple
comparison post test to determine significant differences
between mutant receptors and theWTM1mAChR. A value of
p 0.05 was considered statistically significant.
RESULTS
Identification of Benzoquinazolinone 12 as a Selective Positive
Allosteric Modulator of the M1 mAChR with Higher Affinity
than BQCA—In a patent from Merck (25), a series of aryl
methyl benzoquinazolinone compounds were disclosed as
selective positive allosteric modulators of theM1mAChR. One
such compound, 3-((1S,2S)-2-hydroxycyclohexyl)-6-((6-(1-
methyl-1H-pyrazol-4-yl)pyridin-3-yl)methyl)benzo[h]quina-
zolin-4(3H)-one (referred to herein as benzoquinazolinone 12;
Fig. 1A), was identified as a potent and selective modulator
based on its ability to potentiate a single EC20 concentration of
ACh in a calciummobilization assay (25, 37). We developed an
optimized synthesis, improving the overall yield (Scheme S1 in
the supplemental materials) of this compound, followed by
detailed pharmacological characterization. We performed
whole cell equilibrium competition binding using the radiola-
beled antagonist [3H]NMS to study the interaction between
ACh and benzoquinazolinone 12. An allosteric ternary com-
plex model (Equation 1) was applied to the data to obtain esti-
mates of modulator affinity for the M1 mAChR (pKB), and its
binding cooperativity with ACh (Log ) (Fig. 2 and Table 1).
This revealed that compared with the prototypical M1 mAChR
positive allosteric modulator BQCA, benzoquinazolinone 12
displays a greater than 50-fold increase in affinity for the M1
mAChR (Fig. 1B, KB 15 M and KB 0.3 M, for BQCA and
benzoquinazolinone 12, respectively) while maintaining a sim-
ilar level of positive cooperativity with ACh (Fig. 2A and Table
1). Interestingly, the modulator displayed high negative coop-
erativity with the inverse agonist radioligand, which is also a
property shared by BQCA (11). Moreover, we confirmed the
absolute subtype selectivity of benzoquinazolinone 12 in bind-
Structure-Function Analysis of M1 Receptor Allosteric Ligands
NOVEMBER 28, 2014•VOLUME 289•NUMBER 48 JOURNAL OF BIOLOGICAL CHEMISTRY 33703
 at U
N
IV
 O
F N
O
TTIN
G
H
A
M
 on N
ovem
ber 28, 2014
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
ing studies using cells expressing the M2, M3, M4, and M5
mAChRs. As shown in Fig. 2C, benzoquinazolinone 12 does not
modulate the affinity of ACh at any of these receptor subtypes.
We next extended our characterization of this ligand to func-
tional assays. Using IP1 accumulation as a canonical measure of
M1 mAChR activation resulting from preferential activation of
Gq proteins, and analysis of the data by applying an opera-
tional model of allostery (Equation 2), we found that both func-
tional cooperativity (Log ) and the intrinsic efficacy (Log B)
of benzoquinazolinone 12 were similar to those determined for
BQCA (Table 1 and Fig. 2B). It was of interest, therefore, to
determine the structural basis of the improved allosteric action
of benzoquinazolinone 12 as compared with BQCA at the level
of receptor residues that this ligand engages and confirm
whether benzoquinazolinone 12 engages the same allosteric
site as that which we have proposed for BQCA (10).
N
O
OH
O
O
N
O
N
OH
N
N
N
BQCA Benzoquinazolinone 12
-12 -10 -8 -6 -4 -2
0
50
100
Log [Ligand] (M)
[3
H
]N
M
S 
sp
ec
ifi
c 
bi
nd
in
g
BQCA
A B
FIGURE1.A, chemical structureofM1mAChR-selectivepositiveallostericmodulators.Leftpanel, BQCA.Rightpanel, benzoquinazolinone12.B, BQCAandbenzoquina-
zolinone 12 inhibit the equilibriumbinding of [3H]NMS. Data points represent themeans S.E. of three independent experiments performed in triplicate.
FIGURE 2. Pharmacological characterization of benzoquinazolinone 12, a high affinity positive allosteric modulator of the M1 mAChR. A, whole cell
radioligand competition binding between [3H]NMS and increasing concentrations of ACh in the absence or presence of increasing concentrations of benzo-
quinazolinone 12 in CHO FlpIn cells stably expressingWTM1 mAChR. B, interaction between ACh and benzoquinazolinone 12 in an IP1 accumulation assay in
CHO FlpIn cells stably expressingWTM1mAChR. C, whole cell radioligand competition binding between [
3H]NMS and increasing concentrations of ACh in the
absence or presence of increasing concentrations of benzoquinazolinone 12 in CHO FlpIn cells stably expressing WT M2–5 mAChR. The curves in A and C
represent the best fit of an allosteric ternary complexmodel (Equation 1). The curves in B represent the best fit of an operational allosteric model (Equation 2).
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Effect of Amino Acid Substitution to Ala on the Binding and
Function of Benzoquinazolinone 12—As shown above, our
pharmacological characterization revealed that benzoquinazo-
linone 12 displayed a 50-fold increase in allosteric site affinity as
compared with BQCA (Table 1). Using a structure-function
approach, we next sought to investigate whether benzoquina-
zolinone 12 binds to the same allosteric pocket as BQCA and
the ligand-receptor interactions that govern its binding affinity
and cooperativity with ACh.
We focused our investigation on the three amino acid res-
idues we recently identified as contributing to the BQCA
binding pocket at the M1 mAChR (Tyr-852.64 in TM2, Tyr-
179 in ECL2, and Trp-4007.35 in TM7) (10). In addition, we
included Tyr-822.61 in TM2, which is conserved in the
relatedM2mAChR and previously identified to contribute to
the binding pocket of several allosteric modulators at that
subtype (9, 13, 15). Each of these aromatic residues was
mutated to Ala, and the mutant M1 mAChRs were stably
expressed in FlpIn CHO cells. Only W4007.35A showed
50% reduction in cell surface receptor expression com-
pared with the WT (Table 2). The equilibrium dissociation
constants of the orthosteric antagonist [3H]NMS (pKA) and
the orthosteric agonist ACh (pKI) were significantly reduced
at Y822.61A and Y852.64A, whereas only ACh affinity was
reduced at W4007.35A (Table 2), consistent with previously
published findings (13, 14, 38–40).
We then investigated the effect of each of thesemutations on
the affinity and function of benzoquinazolinone 12. Binding
interaction studies revealed that although the affinity of BQCA
(pKB) and its binding cooperativity with ACh (Log ) were not
affected by the Y822.61A mutation, benzoquinazolinone 12 dis-
played a significantly reduced affinity at this mutant receptor
with no significant change in its binding cooperativity with
ACh (Tables 3 and 4 and Fig. 3, top and middle panels). Simi-
larly, the pKB and Log  of BQCA were not affected by the
Y852.64A mutation; however, the pKB (but not the binding
cooperativity) of benzoquinazolinone 12 were significantly
lower compared with WT. A Tyr in ECL2 (Tyr-179 in the M1
mAChR) has been found in numerous studies to be involved in
the binding of allosteric ligands at the mAChR family (10,
12–15). As shown in Tables 3 and 4 and Fig. 3 (top andmiddle
panels), mutation of this residue has a profound effect on both
BQCA and benzoquinazolinone 12, although mechanistically the
effect onBQCAappears tobe via reduced cooperativitywithACh,
whereas the effect on benzoquinazolinone 12 is a 100-fold
reduction in its affinity for the allosteric site. In contrast, Ala sub-
stitution of the conserved Trp-4007.35 residue in TM7 completely
abolished the binding of both BQCA and benzoquinazolinone 12
(Table 3 and Fig. 3, top and middle panels), suggesting that this
residue is a key direct contributor to the allosteric binding pocket.
It is also interesting tonote that the binding cooperativity between
ACh with benzoquinazolinone 12 was not significantly different
from WT at any of the Ala mutants with the exception of
W4007.35A. As such, these aromatic residues appear to be critical
for the binding of benzoquinazolinone 12but donot participate in
the transfer of cooperativity between benzoquinazolinone 12 and
the ACh binding site.
Analysis of the allosteric modulator effects at the Ala
mutants using an IP1 accumulation assay revealed that the
functional cooperativity (Log ) of benzoquinazolinone 12
with ACh is increased at Y822.61A but not affected by Ala sub-
stitution at Tyr-852.64 (Table 4 and Fig. 3, bottom panel). At
both Y179A andW4007.35A, BQCA showed no potentiation of
ACh. However, in the case of benzoquinazolinone 12 at Y179A,
TABLE 1
Allosteric modulator pharmacological parameters at the WT M1
mAChR
Estimated parameter values represent the means  S.E. of three experiments
performed in duplicate. pKB and Log  values were obtained from analysis of the
binding interaction data with Equation 1, whereas Log  and Log B values
were obtained from analysis of functional interaction data according to
Equation 2.
Ligand pKBa Log b Log c Log Bd
BQCA 4.82 0.09 1.90 0.14 1.54 0.15 0.35 0.07
Benzoquinazolinone 12 6.55 0.03e 2.14 0.06 1.79 0.21 0.87 0.20
aNegative logarithm of the equilibrium dissociation constant of the modulator
b Logarithm of the binding cooperativity factor between the modulator and ACh
as estimated by Equation 1; for this analysis, the pKA of 3HNMS was con-
strained to 9.92, and the cooperativity between 3HNMS with each of the mod-
ulators was constrained to2, consistent with high negative cooperativity be-
tween the two ligands.
c Logarithm of the functional cooperativity between ACh and the modulator.
d Logarithm of the operational efficacy parameter for the modulator.
e Significantly different (p 0.05), from BQCA as determined by one-way
ANOVA with Dunnett’s post hoc test.
TABLE 2
Whole cell equilibrium binding and functional parameters for 3HNMS and ACh at theWT andmutant M1mAChRs
The values represent the means S.E. of three experiments performed in duplicate. ND, not determined.
Bmaxa pKAb pKIc pEC50d Log Ae
M1 WT 415 15 9.92 0.01 5.11 0.08 6.56 0.11 1.74 0.05
Y822.61A 225 7 f,g 9.76 0.01 f,g 4.29 0.07g 5.64 0.10g 1.02 0.08g
Y852.64A 398 10 f 9.82 0.03 f,g 4.65 0.06g 5.23 0.08g 0.57 0.05g
Y179A 270 14 f,g 10.00 0.02 f 5.05 0.08 5.37 0.12g 0.82 0.03g
W4007.35A 138 6 f,g 9.95 0.01 f 4.62 0.08g 4.84 0.04g ND
Y822.61F 280 12g 10.39 0.01g 5.24 0.08 5.59 0.09g 0.96 0.06g
Y852.64F 295 12g 10.04 0.01 4.98 0.09 5.54 0.08g 1.09 0.05g
Y179F 280 10g 9.95 0.07 5.24 0.08 5.68 0.10g 0.94 0.08g
Y179W 304 8g 9.85 0.03 5.08 0.09 5.42 0.09g 0.86 0.09g
W4007.35F 170 12g 10.04 0.01 4.82 0.07 5.29 0.09g 1.00 0.03g
W4007.35Y 230 16g 10.31 0.05g 5.21 0.05 5.86 0.06g 1.28 0.06g
aMaximum density of binding sites per 104 cells in counts/min.
bNegative logarithm of 3HNMS equilibrium dissociation constant.
cNegative logarithm of ACh equilibrium dissociation constant.
dNegative logarithm of the EC50 value.
e Logarithm of the operational efficacy parameter for ACh as estimated by Equation 2, corrected for changes in receptor expression to allow comparison with WT.
f Values taken from the results of Abdul-Ridha et al. (10).
g Significantly different (p 0.05), fromWT value as determined by one-way ANOVA with Dunnett’s post hoc test.
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potentiation was similar to WT but was abolished at the
W4007.35A mutation. The intrinsic efficacy (Log B) of both
BQCA and benzoquinazolinone 12 was abolished at each of the
M1 mAChR Ala mutants with the exception of benzoquinazo-
linone 12 at Y822.61A, where Log B (0.73  0.20) was
unchanged relative to WT values (Table 1).
The combined data from the Ala mutation experiments
reveal that Tyr-179 in ECL2 andTrp-4007.35, residues shown to
be of key importance for the activity of BQCA, are also impor-
tant for the binding of benzoquinazolinone 12. This is consis-
tent with both ligands binding to the same allosteric site within
the M1 mAChR. Furthermore, these results reveal that muta-
tion of Tyr-179 reduces benzoquinazolinone 12 binding affinity
but not cooperativity. It is interesting to note that although
BQCA was unaffected by both Y822.61A and Y852.64A muta-
tions, this was not the case for benzoquinazolinone 12. As such,
the replacement of the methoxy group with an aromatic sub-
stituent at the 4-position of the benzylic pendant of BQCA or
the replacement of the carboxylic acid with the corresponding
3-((1S,2S)-2-hydroxycyclohexyl) group present in benzoquina-
zolinone 12 must confer sensitivity to mutation of these TM2
residues.
Molecular Dynamics Simulations and Ligand Docking of
Benzoquinazolinone 12 and Comparison with BQCA—To
rationalize our findings, we performed ligand docking and
molecular dynamic simulations. This resulted in onemain pose
of benzoquinazolinone 12 in anM1 mAChR in which ACh was
co-bound. This was then compared with the complex of BQCA
with carbachol (CCh) bound to theM1mAChR obtained using
the samemethodology in our previous study (10). The complex
FIGURE 3. Effect ofM1mAChRAlamutations on the binding and function
of BQCAandbenzoquinazolinone 12. The bars represent the difference for
each mutant receptor in allosteric ligand affinity (pKB, top panel), binding
cooperativity value (Log , middle panel), or functional cooperativity value
(Log , bottom panel) of BQCA and benzoquinazolinone 12 relative to WT.
The values are derived from interaction experiments in [3H]NMS radioligand
binding and IP1 accumulation (Tables 3 and 4). *, significantly different (p
0.05) from WT as determined by one-way ANOVA with Dunnett’s post hoc
test. nd, not determined (no allosteric modulation).
TABLE 3
Allostericmodulator equilibriumdissociation constants (pKB) andbinding cooperativity (Log) estimates for the interactionwithAChat theWT
andmutant M1 mAChRs
Estimated parameter values represent the means S.E. of three or four experiments performed in duplicate. pKB is the negative logarithm of the equilibrium dissociation
constant of themodulator, as estimated by Equation 1 from binding interaction studies with ACh; for this analysis, the pKA of 3HNMS for theWT and each of themutants
was constrained to the values listed in Table II. The cooperativity between 3HNMS with each of the modulators was constrained to 2, consistent with high negative
cooperativity between the two ligands. ND, not determined (no allosteric modulation).
pKB Log 
BQCA Benzoquinazolinone 12 BQCA Benzoquinazolinone 12
M1 WT 4.82 0.06 6.55 0.03 1.90 0.14 2.14 0.06
Y822.61A 4.73 0.06 5.28 0.03a 1.96 0.14 2.62 0.15
Y852.64A 4.86 0.08 5.37 0.06a 1.53 0.13 2.08 0.11
Y179A 4.68 0.08 4.56 0.19a 0.16 0.28a 2.18 0.22
W4007.35A ND ND ND ND
Y822.61F 4.99 0.07 5.67 0.07a 1.72 0.14 2.23 0.14
Y852.64F 4.66 0.00 5.86 0.06a 1.35 0.15 2.09 0.15
Y179F 4.72 0.07 6.15 0.05a 1.88 0.13 2.04 0.13
Y179W 5.06 0.05 6.69 0.04 2.11 0.13 1.78 0.14
W4007.35F 4.44 0.08a 5.22 0.08a 0.83 0.16a 2.25 0.15
W4007.35Y 4.27 0.10a 5.34 0.07a 1.50 0.10 2.06 0.14
a Significantly different (p 0.05), fromWT value as determined by one-way ANOVA with Dunnett’s post hoc test.
TABLE 4
Functional cooperativity (Log ) estimates for the interaction
between the allosteric modulators and ACh at theWT andmutant M1
mAChRs
Estimated parameter values represent themeans S.E. of three or four experiments
performed in duplicate. Log  is the logarithm of the functional cooperativity
factor between themodulator andACh as estimated by Equation 2. For this analysis,
the pKI values for AChwere fixed to those determined from the radioligand binding
assays as listed in Table 2. ND, not determined (no allosteric modulation).
Log 
BQCA Benzoquinazolinone 12
M1 WT 1.54 0.15 1.79 0.21
Y822.61A 1.93 0.10 2.76 0.27a
Y852.64A 1.49 0.04 1.96 0.04
Y179A ND 1.82 0.14
W4007.35A ND ND
Y822.61F 1.46 0.20 2.01 0.32
Y852.64F 0.58 0.08a 1.82 0.23
Y179F 1.26 0.15 2.15 0.30
Y179W 1.68 0.11 2.53 0.23
W4007.35F 0.45 0.07a 0.90 0.11
W4007.35Y 1.10 0.11 0.57 0.09a
a Significantly different (p 0.05), fromWT value as determined by one-way
ANOVA with Dunnett’s post hoc test.
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for benzoquinazolinone 12 and ACh bound to the modeledM1
mAChR is shown in Fig. 4. As forCCh in our previous study and
analogous to that observed in receptor crystal structure of the
M2 mAChR in complex with the agonist iperoxo (9), Asp-
1053.32 engages the quaternized choline head group of ACh.
Furthermore, ACh lies within a hydrophobic pocket formed by
residues Tyr-1063.33, Trp-1574.57, Tyr-3816.51, and Tyr-4087.43.
In the BQCA-bound complex, stability is added to this binding
pocket through a network of hydrogen bond interactions
between Tyr-3816.51, Tyr-1063.33, and Tyr-4047.39 (10). These
Tyr residues essentially form an aromatic lid over ACh via cat-
ion- interactions. It is interesting to note that in the case of the
complex with benzoquinazolinone 12 bound, although the
interaction between Tyr-3816.51 and Tyr-1063.33 is maintained,
Tyr-4047.39 faces TM2 and interacts with Tyr-822.61 (Fig. 4).
Analysis of the molecular dynamics trajectories reveals that
both BQCA and benzoquinazolinone 12 adopt a similar pose
(Fig. 5). In both cases, the binding site for the ligands is defined
by residues from TM2, TM7, and ECL2 and is in agreement
with our mutagenesis studies. In particular, the significant
effects of the mutation of Tyr-179 to Ala in ECL2 and Trp-
4007.35 in TM7 on the pharmacology of BQCA and benzo-
quinazolinone 12 can be reconciled with the poses of each
ligand. In both BQCA and benzoquinazolinone 12 complexes,
Tyr-179 is predicted to contribute to the stable binding of the
compounds via hydrophobic/edge to face- interactionswith
the bicyclic 4-oxoquinoline core of BQCA or tricyclic benzo-
[h]quinazolin-4(3H)-one core of benzoquinazolinone 12. In
addition, the hydroxyl group of Tyr-179 may form a polar or
potential hydrogen bond interaction with the OH group of the
3-((1S,2S)-2-hydroxycyclohexyl) moiety of benzoquinazolin-
one 12. This interaction cannot take place in the BQCA bound
complex, because BQCA does not bear the corresponding
amidemoiety. Trp-4007.35 is predicted to interact with the ben-
zylic pendant of both BQCA and benzoquinazolinone 12. How-
ever, in the BQCA bound complex, Trp-4007.35 is positioned
horizontally below the benzylic pendant of BQCA and is pre-
dicted tomake a- stacking interaction with this moiety (Fig.
5A). In comparison, to accommodate the additionalN-methyl-
pyrazole substituent of benzoquinazolinone 12, Trp-4007.35 is
positioned in a more vertical orientation and extends toward
TM6. This orientation allows the following interactions: (a)
edge to face -/hydrophobic interactions with theN-methyl-
pyrazole substituent of benzoquinazolinone 12, (b) hydropho-
bic sandwich of pyrazole substituent between Trp-4007.35 and
Tyr-179, (c) a - stacking interaction with Phe-182 in ECL2,
FIGURE 4. Structural homologymodel of theM1mAChR complex co-bound
with CCh-BQCA (orange) or ACh-benzoquinazolinone 12 (blue). The overall
structure of the BQCA-bound M1 mAChR model (orange) is similar to that of
thebenzoquinazolinone12-boundM1mAChRmodel (blue). ACh (pink), BQCA
(orange), and benzoquinazolinone 12 (blue) are shown as spheres colored
according to element. Top inset, overlay of the BQCA (orange) and benzo-
quinazolinone 12 (blue) poses represented as stick structures. Bottom inset,
ACh binding site in benzoquinazolinone 12-bound M1 mAChR complex
model. Important residues are shown as sticks.
FIGURE 5.Proposed arrangement of the binding sites of BQCAandbenzoquinazolinone 12 at theM1mAChR.A, extracellular viewof the binding sites of
BQCA and benzoquinazolinone 12. BQCA (orange) and benzoquinazolinone 12 (blue) are shown as spheres colored according to element. Important residues
are shown as sticks. Insets, positions of Tyr-22.61, Tyr-852.64, Tyr-4047.39, Tyr-179, Phe-182, and Trp-4007.35 in the ACh-benzoquinazolinone 12-boundM1mAChR
model. B, extracellular view of the BQCA-bound (orange) and benzoquinazolinone 12-bound (blue) M1 mAChR models showing a tighter pocket for benzo-
quinazolinone 12 as compared with that predicted for BQCA.
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which appears to pull ECL2 toward TM7, creating a tighter
allosteric binding pocket as comparedwith that observed in the
BQCA bound complex (Fig. 5, A and B). The additional inter-
actions observed in the complex with benzoquinazolinone 12
can explain, in part, the increased affinity of benzoquinazolin-
one 12 as compared with BQCA. The TM2 residues Tyr-852.64
andTyr-822.61 are predicted to delimit the allosteric site in both
complexes via edge to face -/hydrophobic interactions with
the 4-oxoquinoline ring system in the case of BQCA. However,
the tricyclic core of benzoquinazolinone 12 is closer to TM2
(Fig. 5A), allowing interactionswith both residues, whichmay
also contribute to the higher binding affinity of benzoquinazo-
linone 12. In agreement with this pose, mutation of both Tyr-
852.64 and Tyr-822.61 caused a greater than 10-fold loss of affin-
ity for benzoquinazolinone 12, whereas no effect upon the
affinity of BQCA was observed. The closer interaction of Tyr-
822.61 with benzoquinazolinone 12 may allow for increased
ligand-receptor hydrophobic interactions that may account for
the higher binding affinity of this ligand at the allosteric binding
site (Fig. 5, A and B). Of interest, Tyr-822.61 makes a H-bond
interaction with Tyr-4047.39, one of the residues that forms the
aromatic ‘lid’ over the CCh binding site in the BQCA bound
complex. As such, this interaction may provide part of the
cooperativemechanism throughwhich binding of benzoquina-
zolinone 12 to the allosteric pocket modulates the shape of and
ligand receptor interactions within the orthosteric pocket.
Effect of ConservativeAminoAcid Substitution on theBinding
and Function of BQCA and Benzoquinazolinone 12—Our
mutagenesis and modeling studies highlight the particular
importance of Tyr-852.64 and Tyr-822.61 in TM2, Tyr-179 in
ECL2, and Trp-4007.35 in TM7. However, such an Ala scanning
approach, although useful to highlight the importance of indi-
vidual residues for the binding of a ligand, can only give limited
information regarding the nature of these interactions. In par-
ticular our modeling studies suggested that Tyr-852.64, Tyr-
822.61, and Tyr-179 might participate in a hydrogen bond net-
work with the ligand and/or with other residues in the complex
with benzoquinazolinone 12 but not in the BQCA complex. To
further understand the contribution of each of the aromatic
amino acid residues to the allosteric binding pocket, we tested
the effects of more subtle amino acid substitutions on ligand
binding and function. We mutated each Tyr residue (Tyr-
822.61, Tyr-852.64, and Tyr-179) or Trp-4007.35 to Phe. In addi-
tion, we mutated Tyr-179 to Trp with the expectation that this
larger, bicyclic aromatic residuewould be able tomake stronger
interactions with the benzylic pendant of both ligands as sug-
gested from our BQCA analogues SAR data (41), Ala mutation
data, and modeling results. We compared the effects of these
mutations upon the pharmacology of both BQCA and benzo-
quinazolinone 12 (Fig. 6).
As with the Ala substitutions, we first tested the effects of the
mutants on orthosteric ligand binding and cell surface receptor
expression. Whole cell [3H]NMS saturation binding experi-
ments showed that all the mutations led to a significant reduc-
tion in cell surface receptor expression compared with theWT
(Table 2). The maximum decrease in receptor expression rela-
tive toWTwas2-fold at Trp-4007.35F. In addition to receptor
expression, the equilibrium dissociation constant of the
orthosteric antagonist [3H]NMS (pKA) or the orthosteric ago-
nist ACh (pKI) were also determined (Table 2). Y822.61F and
W4007.35Y caused slight but significant increases in [3H]NMS
affinity. The remaining mutants had no effect on orthosteric
ligand binding. The potency (EC50) of ACh in IP1 assays was
significantly reduced at all the mutants, likely because of the
reduction in receptor surface expression (Table 2).
To determine the effects of each mutant on allosteric ligand
binding affinity (pKB) and cooperativity (Log ) with ACh, we
performed whole cell binding interaction studies for both
BQCA and benzoquinazolinone 12. The pKB and Log  of
FIGURE 6. Effect of M1 mAChR conservative mutations on the binding
and function of BQCA and benzoquinazolinone 12. The bars represent
the difference for each mutant receptor in allosteric ligand affinity (pKB,
top panel), binding cooperativity value (Log ,middle panel), or functional
cooperativity value (Log , bottom panel) of BQCA and benzoquinazoli-
none 12 relative to WT. The values are derived from interaction experi-
ments in [3H]NMS radioligand binding and IP1 accumulation (Tables 3 and
4). *, significantly different (p 0.05) from WT as determined by one-way
ANOVA with Dunnett’s post hoc test.
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BQCA were unchanged at the Tyr to Phe mutants (Y852.64F,
Y822.61F, and Y179F) (Table 3), suggesting that the ability of
these residues tomake hydrophobic, rather than polar, interac-
tions is predominant for their role in BQCA binding and
function. In contrast, substitution of the conserved aromatic
residue Trp-400 to less bulky aromatic amino acids (W4007.35F
and W4007.35Y) caused significant reductions in BQCA and
benzoquinazolinone 12 binding affinity (Table 3). Interestingly,
substitution of Tyr-852.64 and Tyr-822.61 in TM2 and Tyr-179
in ECL2 to Phe resulted in significant decreases in the binding
affinity of benzoquinazolinone 12. This suggests that the ability
to make polar interactions has a significant contribution to
their role in the binding of benzoquinazolinone 12 and is in
agreement with the network of interactions predicted by our
modeling experiments. Replacement of Tyr-179 with a Trp did
not significantly change the affinity of either BQCA or benzo-
quinazolinone 12. The binding cooperativity of BQCA with
ACh was only reduced at W4007.35F (Table 3). Interestingly,
and in agreement with the results at the corresponding Ala
mutants, the binding cooperativity of benzoquinazolinone 12
with ACh was not significantly changed at any of these conser-
vative mutants (Table 3).
We extended our study to look at the effect of these muta-
tions upon the action of BQCA and benzoquinazolinone 12 in a
functional assay. Analysis of the allosteric potentiation of ACh
by BQCA in an IP1 accumulation assay revealed that the func-
tional cooperativity was profoundly reduced at Y852.64F and
W4007.35F, although benzoquinazolinone 12 showed reduced
cooperativity with ACh at W4007.35Y but not the other muta-
tions. Both ligands showed unchanged cooperativity at Y179W
(Table 4), in agreement with the binding results.
DISCUSSION
Significant efforts have been directed at the discovery of
novel selective ligands of the M1 mAChR as a therapeutic
approach for neurocognitive disorders, such asAlzheimer’s dis-
ease (3, 42). From these efforts, the compounds that display the
most exquisite selectivity target an allosteric site of this recep-
tor, as exemplified by BQCA (6, 12). More recently, benzo-
quinazolinone 12, an analogue of BQCA, was described as a
modulator with improved allosteric activity (25). We have now
provided a detailed characterization of benzoquinazolinone 12,
demonstrating that its increase in activity at the M1 mAChR as
compared with BQCA is largely derived from an approximately
50-fold increase in affinity, whereas both functional and bind-
ing cooperativity with ACh are not substantially changed. Fur-
thermore, benzoquinazolinone 12 not only displays high posi-
tive cooperativity with agonist binding but also high negative
cooperativity with the binding of the orthosteric antagonist
[3H]NMS. Thus, benzoquinazolinone 12 appears to conform to
the classic Monod-Wyman-Changeux mechanism of action
previously described for BQCA (11).
Our previous SAR study of derivatives of BQCA revealed
four discrete areas of structural modification that conferred
distinct effects on the allosteric activity of these compounds
(41). Alternative substitution of the 5- and 8-positions of the
quinolone ring appeared to modulate intrinsic efficacy (B);
isosteric replacement of the carboxylic acid moiety or amide
derivatives modulated cooperativity parameters ( and ) and,
finally, replacement of the pendant N-alkyl group modulated
affinity (pKB). The ability to enrich allosteric SAR by dissecting
these molecular parameters can also be used to link these
parameters to receptor structural information, thus yielding
new insights into the structural basis of allostery. In the current
study, we applied this approach to explore the structural basis
of the improved allosteric activity of benzoquinazolinone 12 at
the M1 mAChR in comparison to BQCA. This is important,
because the location and nature of the allosteric site for most
GPCRs remains poorly characterized. Our combinedmutagen-
esis and molecular modeling experiments provide evidence
that BQCAand benzoquinazolinone 12 occupy a similar pocket
of the M1 mAChR. In our previous study, we proposed that
Tyr-179 (in ECL2) and Trp-4007.35 were of key importance for
the activity of BQCA (10). In the current work, we confirmed
this result and found that the W4007.35A mutation abrogated
detectable binding of compound benzoquinazolinone 12,
whereas the compound also displayed a 100-fold decrease in
affinity at the Y179Amutant. However, this lattermutation had
no effect upon the cooperativity of benzoquinazolinone 12. In
agreement with the role of Tyr-179 as a determinant of both
BQCA and benzoquinazolinone 12 affinity or transmission of
cooperativity, ourmodeling studies reveal that this residue pro-
vides hydrophobic/edge to face - interactions with the bicy-
clic core of BQCA or tricyclic core of benzoquinazolinone 12,
although the rotameric orientation of the residue differs slightly
depending on themolecule bound. Indeed,mutation of this Tyr
to the aromatic residues Phe or Trp had no effect, confirming
that Tyr-179 makes predominantly hydrophobic interactions
with both ligands. Trp-4007.35 is predicted to interact with the
benzylic pendant of both BQCA and benzoquinazolinone 12.
Indeed, the importance of this interaction is validated both by
our structure-function analysis and by the SAR of BQCAderiv-
atives (41) and benzoquinazolinone 12. The mutation of Trp-
4007.35 to Ala completely abolished detectable binding of all
allostericmodulators in this study. Furthermore, the additional
aromatic substitution of the 4-position of the benzylic pendant
conferred a gain in affinity. Such substitutions would enhance
the ability of these ligands to make hydrophobic interactions
with Trp-4007.35. In agreement with this hypothesis, the con-
servative mutation of Trp-4007.35 to the smaller Phe or Tyr
conferred decreases in affinity. In the BQCA-bound complex
Trp-4007.35 is positioned horizontally below the benzylic pen-
dant of BQCA and makes a - stacking interaction with this
moiety. In comparison, to accommodate the additional pyr-
azole substituent of benzoquinazolinone 12, Trp-4007.35 is
positioned in a more vertical orientation and extends toward
TM6. This change in orientation allows the pyrazole substitu-
ent of benzoquinazolinone 12 to make hydrophobic interac-
tions with both Trp-4007.35 and Tyr-179. Of interest, in theM2
mAChR crystal structure, Trp-4227.35 adopts a vertical confor-
mation in the presence of the positive allosteric modulator
LY2119620 and a horizontal conformation with iperoxo alone.
The vertical conformation of this residue in the M2-iperoxo-
LY2119620 complex allows it to engage in an aromatic stacking
interaction with the modulator (9).
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The TM2 residues Tyr-852.64 and Tyr-822.61 are predicted to
line the allosteric pocket in both BQCA and benzoquinazolin-
one 12-bound complexes. However, the tricyclic core of benzo-
quinazolinone 12 is predicted to be closer to TM2, conferring
stronger interactions with both residues, whichmay contribute
to the higher binding affinity of benzoquinazolinone 12. In
agreement with this pose, mutation of both Tyr-852.64 and Tyr-
822.61 to Ala caused a greater than 10-fold loss of affinity for
benzoquinazolinone 12, whereas no effect upon the affinity of
BQCA was observed. Tyr-822.61 was predicted to make a
H-bond interaction with Tyr-4047.39 in the benzoquinazolin-
one 12-bound complex but not in the BQCA-bound complex.
Interestingly, mutation of Tyr-822.61 to Phe caused a significant
decrease in the pKB of benzoquinazolinone 12 for the mutant
receptor but not BQCA. Tyr7.39 has been shown to play a key
role in the binding of the orthosteric ligand iperoxo in the active
structure of the M2 mAChR, forming an aromatic lid over the
ligand amine, an interaction present in our BQCA bound com-
plex. Indeed, this residue has been shown to play an important
role in orthosteric ligand binding at a number of GPCRs. Of
interest,mutationof thecorrespondingresidue in theM4mAChR
caused a significant decrease in the binding cooperativity of the
positive allostericmodulator LY2033298withACh (14). This sug-
gests that this residue is also important for transferof cooperativity
between the allosteric andorthosteric binding sites. It is also inter-
esting to note that the additional pyrimidinone ring in benzo-
quinazolinone 12 is predicted to be positioned above the allosteric
binding pocket. Although the functional significance of this por-
tion of themodulator has not yet been investigated through struc-
ture-activity relationships, a recent report by Kuduk et al. (44)
highlights the importance of the intramolecular hydrogen bond
between the 4-oxomoiety and 3-carboxylic acid group present in
bicyclic BQCA-type scaffolds, suggesting that this hydrogen bond
is key for allosteric activity.Wehypothesize that the pyrimidinone
ring that forms part of the tricyclic core in benzoquinazolinone 12
formalizes the rigidity imparted by this intramolecular hydrogen
bond.
Dror et al. (13) recently used molecular dynamics to identify
two binding centers in the extra cellular vestibule of the M2
mAChR that are implicated in the binding of several structurally
diverse positive and negative allosteric modulators, each of the
binding centers is defined by a pair of aromatic residues (Centre 1
Tyr-177ECL2 andTrp7.35, Centre 2 Tyr2.61, andTyr2.64). Addition-
ally, theM2mAChR crystal structure co-bound by the orthosteric
agonist iperoxo and the positive allosteric modulator LY2119620
shows that the aromatic rings of the modulator are situated
directly between Tyr-177 in ECL2 and Trp-4227.35, forming a
three-layered aromatic stack (9). A previous mutagenesis study
implicated Tyr-177 as a contact for the LY2119620 congener
LY2033298 at theM2mAChRs (43).We identified the equivalent
M1mAChR residues as key contributors for the binding and func-
tion of BQCA (10) and benzoquinazolinone 12. In particular,
because benzoquinazolinone 12displays significantly higher affin-
ity than BQCA, we were able to demonstrate that Tyr-179 has a
major role in the binding of allosteric ligands or in the transfer of
cooperativity. Tyr2.64 andTrp7.35 are conserved across allmAChR
receptor subtypes, Tyr2.61 is conserved across all but the M3
mAChR(where it is a similarly aromaticPhe residue), andTyr-179
is only present at the M1 andM2 mAChRs but is a Phe at the M3
andM4mAChRs. This is consistentwith BQCAand its analogues
sharing a common binding site with other prototypical mAChR
allostericmodulators.Althoughthese findingsprovide insight into
the location of the binding pocket for mAChR allosteric modula-
tors, they do not explain how some of these ligands achieve
subtype selectivity. As we hypothesized in our earlier studies, it is
likely that receptor subtype selectivity is achieved via selective
cooperativity of the modulators with the orthosteric ligands.
In summary, our combined mutagenesis and molecular
dynamics simulations have validated the allosteric binding
pocket we previously described for BQCA and provided a
mechanistic basis for observed SAR of M1 mAChR positive
allosteric modulators. In particular, we have demonstrated that
benzoquinazolinone 12 displays a significant increase in affinity
at the M1 mAChR and identified the ligand-receptor interac-
tions that confer this increase. These insights will provide the
basis for the development of novel M1 mAChR selective allo-
steric ligands that explore new chemical space.
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